Pharmaceuticals, Biotechnology and Life Sciences
Novigenix and RadioMEdix have announced collaboration on developing a test to measure response to radiopharmaceutical therapy, based on Novigenix’s technology.
Novigenix SA, a leading Immuno-Transcriptomics company that develops and
commercializes products for early cancer detection and precision
medicine, today announced the appointment of Francois Martelet, M.D., to
its Board of Directors as a non-executive director. Dr. Martelet has
over 25 years’ experience at both corporate and operational level in
pharmaceutical and biotech companies.